Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H14ClN3O4S |
Molecular Weight | 367.809 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)[C@]([H])(C(=N[C@]2([H])C(=O)N3C(=C(CS[C@]23[H])Cl)C(=O)O)O)N
InChI
InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
DescriptionSources: https://www.drugs.com/pro/cefaclor.htmlCurator's Comment:: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290
Sources: https://www.drugs.com/pro/cefaclor.html
Curator's Comment:: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/666290
Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549 |
1.15 mM [Ki] | ||
Target ID: CHEMBL4605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549 |
4.52 mM [Ki] | ||
Target ID: CHEMBL1743125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16434549 |
65.0 µM [Ki] | ||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
|||
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
|||
Sources: https://www.drugs.com/pro/cefaclor.html |
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
||
Sources: https://www.drugs.com/pro/cefaclor.html |
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
||
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
|||
Curative | CEFACLOR Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing strains of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae. Secondary bacterial infections of acute bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant strains), Moraxella catarrhalis, or Streptococcus pneumoniae. (See above NOTE.) Pharyngitis and tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes. Launch Date1.03109761E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2393282/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEFACLOR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: |
Other AEs: Hypersensitivity... Other AEs: Hypersensitivity (1.5%) Sources: |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: |
Other AEs: Creatinine serum increased... Other AEs: Creatinine serum increased (1 patient) Sources: |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Other AEs: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased (1 patient) Sources: ALT increased (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Other AEs: Eosinophilia, Pruritus genital... Other AEs: Eosinophilia (1 patient) Sources: Pruritus genital (1 patient) Moniliasis (1 patient) Vaginitis (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Other AEs: Alkaline phosphatase increased, Blood urea increased... Other AEs: Alkaline phosphatase increased (1 patient) Sources: Blood urea increased (1 patient) |
250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: |
Other AEs: Diarrhea... Other AEs: Diarrhea (1 patient) Sources: |
20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: |
unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: |
Other AEs: Reaction serum sickness-like... Other AEs: Reaction serum sickness-like (0.5%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypersensitivity | 1.5% | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: infections Age Group: adult Sources: |
Creatinine serum increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 200 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 200 Sources: |
ALT increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Aspartate aminotransferase increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 40 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 40 Sources: |
Eosinophilia | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Moniliasis | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Pruritus genital | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Vaginitis | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 50 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 50 Sources: |
Alkaline phosphatase increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Blood urea increased | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 500 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 500 Sources: |
Diarrhea | 1 patient | 250 mg 3 times / day steady, oral Dose: 250 mg, 3 times / day Route: oral Route: steady Dose: 250 mg, 3 times / day Sources: |
unhealthy, adult n = 70 Health Status: unhealthy Condition: infections Age Group: adult Population Size: 70 Sources: |
Reaction serum sickness-like | 0.5% | 20 mg/kg/day 3 times / day steady, oral Dose: 20 mg/kg/day, 3 times / day Route: oral Route: steady Dose: 20 mg/kg/day, 3 times / day Sources: |
unhealthy, pediatric Health Status: unhealthy Condition: infections Age Group: pediatric Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Recurrent temporal petrositis. | 2001 Apr |
|
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. | 2001 Jan |
|
The near fatal lick. | 2001 Jan |
|
Drug resistant Haemophilus influenzae from respiratory tract infection in a tertiary care hospital in north India. | 2001 Jan-Mar |
|
Spectrophotometric determination of selected cephalosporins in drug formulations using flow injection analysis. | 2001 Jul |
|
Serum sickness-like reaction to cefaclor. | 2001 Jun |
|
Evaluation of oral antimicrobial agent levels in tooth extraction sites. | 2001 Jun |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase. | 2001 Sep 7 |
|
Levofloxacin: an updated review of its use in the treatment of bacterial infections. | 2002 |
|
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000. | 2002 |
|
Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans. | 2002 Apr |
|
Cutaneous and systemic manifestations of drug-induced vasculitis. | 2002 Jan |
|
Comparative study of cefaclor AF vs. cefuroxime axetil in acute exacerbations of chronic bronchitis. | 2002 Jan |
|
Differentiation of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae from other H. influenzae strains by a disc method. | 2002 Mar |
|
The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. | 2002 Mar |
|
An evaluation of cefaclor in Pakistani children with pharyngotonsillitis. | 2002 Oct |
|
[Antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated in major hospitals in Nagano Prefecture]. | 2002 Oct |
|
Mycobacterium bohemicum cervical lymphadenitis. | 2002 Oct |
|
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains. | 2002 Sep |
|
Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. | 2002 Sep |
|
Synthesis and biological activity of tris- and tetrakiscatecholate siderophores based on poly-aza alkanoic acids or alkylbenzoic acids and their conjugates with beta-lactam antibiotics. | 2003 |
|
A case of baboon syndrome associated with group a streptococcal infection. | 2003 Jan |
|
Surveillance of antibiotic resistance in clinical isolates of Streptococcus pneumoniae collected in Belgium during winter 2000-2001. | 2003 Mar-Apr |
|
Antibiotic prophylaxis by low-dose cefaclor in children with vesicoureteral reflux. | 2003 May |
|
[Hypersensitivity reactions to beta-lactam antibiotics in childhood]. | 2003 May-Jun |
Sample Use Guides
The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/666290
Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175488
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
WHO-ATC |
J01DC04
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
||
|
NDF-RT |
N0000011161
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53994-73-3
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
4086
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
3Z6FS3IK0K
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
C76033
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
SUB06163MIG
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
DB00833
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
1450910
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | RxNorm | ||
|
53994-73-3
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
M3184
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | Merck Index | ||
|
258-909-5
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY | |||
|
51039
Created by
admin on Sat Jun 26 04:31:56 UTC 2021 , Edited by admin on Sat Jun 26 04:31:56 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)